GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

The GABAergic neurotransmitter system plays a central role in regulating anxiety and neuronal excitability, making it a key target for understanding anxiolytic therapies. This study by Filatova, Kasian, Kolomin, and colleagues investigated how Selank affects the expression of genes involved in GABAergic neurotransmission in human neuroblastoma cells.

The researchers treated IMR-32 cells with Selank and analyzed changes in gene expression patterns related to GABA signaling, comparing the peptide's effects to those of GABA itself and the antipsychotic olanzapine. This molecular approach provided detailed insights into how Selank influences the fundamental neurotransmitter pathways that regulate mood and anxiety.

The results revealed that Selank modulates the expression of genes involved in GABAergic neurotransmission, providing direct molecular evidence for its anxiolytic mechanism of action. The peptide influenced gene expression in ways that support enhanced GABAergic signaling, which is associated with reduced anxiety and improved neuronal regulation.

This molecular evidence strengthens the scientific foundation for Selank's use as an anxiolytic peptide. By demonstrating specific effects on GABAergic gene expression, the study provides a mechanistic rationale that supports Selank's potential for treating anxiety and other neurological disorders through well-characterized biological pathways.